A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, multi-center, phase 3 study of napabucasin plus weekly
nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine for adult
patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Phase:
Phase 3
Details
Lead Sponsor:
Boston Biomedical, Inc Sumitomo Dainippon Pharma Oncology, Inc